Business Context and Reporting Period
Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A global eye health company operating in three segments: Vision Care (contact lenses, OTC eye care), Pharmaceuticals (prescription eye medications), and Surgical (medical devices and equipment). The Company remains a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 87% of outstanding shares. A separation from BHC is ongoing but subject to debt leverage targets and regulatory approvals.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $1,394 | $2,638 |
| Operating Income | $83 | $116 |
| Net Loss (Attributable to B+L) | $(14) | $(85) |
| Diluted Loss Per Share | $(0.04) | $(0.24) |
| Operating Cash Flow | N/A | $185 |
| Total Debt (Principal) | $5,128 | $5,128 |
| Cash & Cash Equivalents | $367 | $367 |
| Weighted Avg. Interest Rate | 7.43% | 7.43% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% year-over-year for both the quarter and six-month periods. Growth was driven by increased net realized pricing ($59M Q2, $97M YTD), volume increases ($47M Q2, $76M YTD), and favorable foreign currency impacts ($12M Q2, $54M YTD).
- Profitability Improvement: Operating income improved significantly from a loss of $11M in Q2 2025 to $83M in Q2 2026. For the six months, operating income turned from a $94M loss to an $116M profit. This was primarily due to higher contribution margins and reduced interest expense.
- Interest Expense Reduction: Interest expense decreased by $35M in Q2 and $32M YTD compared to the prior year, attributed to the write-off of financing costs from the June 2025 Credit Facility Amendment and lower rates on the January 2031 Refinancing Term Facility.
- Segment Performance:
- Vision Care: Revenue up 4% (Q2) and 6% (YTD), driven by SiHy Daily lenses and dry eye portfolio.
- Pharmaceuticals: Revenue up 15% (Q2) and 14% (YTD), driven by MIEBO and XIIDRA.
- Surgical: Revenue up 19% (Q2) and 13% (YTD), driven by premium IOLs following the resolution of the 2025 enVista recall.
- Asset Impairments: Recorded $9M in asset impairments in Q2 2026 related to a change in a product's future forecasted revenue.
Guidance, Outlook, Risks, and Unusual Items
- Separation from BHC: The Company continues to evaluate the separation from BHC, which may occur via a distribution, sale, or monetization. Completion is contingent on achieving targeted debt leverage ratios and regulatory approvals. No assurance is given that the separation will occur.
- Debt Refinancing: In January 2026, the Company entered a refinancing transaction creating a $2.8B term facility maturing in 2031. The weighted average interest rate on debt is 7.43%.
- Regulatory & Legal:
- FDA Inspection: In June 2026, the FDA issued an Official Action Indicated (OAI) for the Tampa, Florida facility. The Company has completed corrective actions and requested a re-inspection.
- Litigation: Accrued $13M for probable loss contingencies. Ongoing matters include antitrust litigation (BHC/Bausch + Lomb), product liability (Shower to Shower talc claims, indemnified by J&J), and a Doctors Allergy Formula lawsuit where a jury returned a split verdict in May 2026.
- Geopolitical & Trade Risks: The Company is monitoring the impact of U.S. tariffs (including a 100% tariff on patented pharmaceuticals) and conflicts in Russia/Ukraine and the Middle East. Revenues from Russia/Ukraine/Belarus represent ~3% of total revenue; Middle East impact is ~2%.
- Product Pipeline:
- Whitecap Biosciences: A Phase 2 study for a glaucoma neuroprotective candidate failed to meet its primary endpoint in July 2026; the program will not be advanced as a topical eye drop.
- Lumify NXT: NDA submitted; approval anticipated in H1 2027.
- ELIOS: U.S. launch anticipated in H2 2026.
Investor Verification Checklist
- Separation Timeline: Verify the status of debt leverage ratios required to trigger the distribution or sale transaction from BHC.
- FDA Re-inspection: Monitor the outcome of the requested re-inspection of the Tampa facility following the OAI.
- Debt Covenants: Confirm continued compliance with the maximum first lien net leverage ratio covenant (currently 5.75:1.00) under the June 2030 Revolving Credit Facility.
- Legal Exposure: Track the status of the Doctors Allergy Formula motion for judgment notwithstanding the verdict and potential impacts on the $23M+ claim.
- Tariff Impact: Assess the financial impact of the 100% tariff on patented pharmaceuticals and the success of any refund claims or supply chain shifts.